Roivant Sciences Ltd. (ROIV) Tops Q3 EPS by 634c

Roivant Sciences Ltd. (NASDAQ: ROIV) reported Q3 EPS of $6.03, $6.34 better than the analyst estimate of ($0.31). Revenue for the quarter came in at $37.14 million versus the consensus estimate of $32.41 million.

For earnings history and earnings-related data on Roivant Sciences Ltd. (ROIV) click here.

You May Also Be Interested In

• Blue Owl leads $2.4 billion debt deal for Iren data center
• Marvell (MRVL) Stock: Risk/Reward Skewed to the Upside Near-Term Following Selloff, Says Analyst
• FDA approves Roivant's brepocitinib pill for dermatomyositis